121 related articles for article (PubMed ID: 2137367)
21. Plasma estrone and estrone sulphate in breast cancer patients treated with the aromatase inhibitor CGS 16949A.
Klepp R; Lønning PE; Kvinnsland S
Acta Oncol; 1990; 29(4):469-71. PubMed ID: 2143909
[No Abstract] [Full Text] [Related]
22. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
Dowsett M; Jones A; Johnston SR; Jacobs S; Trunet P; Smith IE
Clin Cancer Res; 1995 Dec; 1(12):1511-5. PubMed ID: 9815951
[TBL] [Abstract][Full Text] [Related]
23. Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancer.
Falkson G; Raats JI; Falkson HC
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):161-5. PubMed ID: 1388048
[TBL] [Abstract][Full Text] [Related]
24. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.
Lønning PE; Jacobs S; Jones A; Haynes B; Powles T; Dowsett M
Br J Cancer; 1991 May; 63(5):789-93. PubMed ID: 1828173
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.
Chow LW; Yip AY; Loo WT; Toi M
Cancer Lett; 2008 Apr; 262(2):232-8. PubMed ID: 18248884
[TBL] [Abstract][Full Text] [Related]
26. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.
Dowsett M; Cunningham DC; Stein RC; Evans S; Dehennin L; Hedley A; Coombes RC
Cancer Res; 1989 Mar; 49(5):1306-12. PubMed ID: 2917360
[TBL] [Abstract][Full Text] [Related]
27. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Miller WR; Stuart M; Sahmoud T; Dixon JM
Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
[TBL] [Abstract][Full Text] [Related]
28. Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.
Demers LM
Breast Cancer Res Treat; 1994; 30(1):95-102. PubMed ID: 7949208
[TBL] [Abstract][Full Text] [Related]
29. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A
Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711
[TBL] [Abstract][Full Text] [Related]
30. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
Goss PE; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Gazet JC; Coombes RC
Cancer Res; 1986 Sep; 46(9):4823-6. PubMed ID: 2942241
[TBL] [Abstract][Full Text] [Related]
31. Recent progress in development of aromatase inhibitors.
Santen RJ
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1029-35. PubMed ID: 2149503
[TBL] [Abstract][Full Text] [Related]
32. Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma.
Costa LA; Kopreski MS; Demers LM; Chinchilli VM; Santen RJ; Harvey HA; Lipton A
Cancer; 1999 Jan; 85(1):100-3. PubMed ID: 9921980
[TBL] [Abstract][Full Text] [Related]
33. Effect of aromatase inhibitors on estrogen 2-hydroxylase in rat liver.
Purba HS; King EJ; Richert P; Bhatnagar AS
J Steroid Biochem Mol Biol; 1994 Feb; 48(2-3):215-9. PubMed ID: 8142297
[TBL] [Abstract][Full Text] [Related]
34. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Dowsett M; Pfister C; Johnston SR; Miles DW; Houston SJ; Verbeek JA; Gundacker H; Sioufi A; Smith IE
Clin Cancer Res; 1999 Sep; 5(9):2338-43. PubMed ID: 10499602
[TBL] [Abstract][Full Text] [Related]
35. ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer.
Buzdar AU; Jonat W; Howell A; Plourde PV
J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):145-9. PubMed ID: 9365184
[TBL] [Abstract][Full Text] [Related]
36. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model.
Yue W; Wang J; Savinov A; Brodie A
Cancer Res; 1995 Jul; 55(14):3073-7. PubMed ID: 7606729
[TBL] [Abstract][Full Text] [Related]
37. Early phase II study of the new aromatase inhibitor YM511 in postmenopausal patients with breast cancer. Difficulty in clinical dose recommendation based on preclinical and phase I findings.
Tominaga T; Suzuki T
Anticancer Res; 2003; 23(4):3533-42. PubMed ID: 12926103
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A.
Steele RE; Mellor LB; Sawyer WK; Wasvary JM; Browne LJ
Steroids; 1987; 50(1-3):147-61. PubMed ID: 2973160
[TBL] [Abstract][Full Text] [Related]
39. Potency and specificity of CGS-16949A as an aromatase inhibitor.
Santen RJ; Langecker P; Santner SJ; Sikka S; Rajfer J; Swerdloff R
Endocr Res; 1990; 16(1):77-91. PubMed ID: 2139412
[TBL] [Abstract][Full Text] [Related]
40. Clinical and endocrine effects of leuprorelin acetate in pre- and postmenopausal patients with advanced breast cancer.
Dowsett M; Jacobs S; Aherne J; Smith IE
Clin Ther; 1992; 14 Suppl A():97-103. PubMed ID: 1606596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]